← 返回首页
美国 · 平台与数据 · Yahoo Finance

Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule

来源:Yahoo Finance · 美国 9 小时前

Johnson & Johnson (NYSE:JNJ) today announced promising Phase 1 results for JNJ-6143 (formerly HLD-0915), an investigational once-daily oral Regulated Induced Proximity Targeting…

在 Yahoo Finance 阅读全文 登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (finance.yahoo.com)

推荐阅读